HCPCS Level II · Drugs administered other than oral method
J9199Injection, gemcitabine hydrochloride (infugem), 200 mg
Terminated 06/30/2020
Source: CMS HCPCS quarterly update, October 2026. Page updated September 29, 2026.
About J9199
J9199 is an HCPCS Level II code in the J series (drugs administered other than oral method), describing injection, gemcitabine hydrochloride (infugem), 200 mg.
It was added to HCPCS effective 01/01/2020, and its current record took effect 07/01/2020.
It was terminated on 06/30/2020 and can't be billed for later dates of service.
Its Medicare coverage code is "C", meaning coverage is left to the Medicare contractor's judgment.
Details
- Short description
- Injection, infugem, 200 mg
- Date added
- 01/01/2020
- Action effective
- 07/01/2020
- Termination date
- 06/30/2020
- BETOS
- O1D
Related J91xx codes
- J9100Injection, cytarabine, 100 mg
- J9118Injection, calaspargase pegol-mknl, 10 units
- J9119Injection, cemiplimab-rwlc, 1 mg
- J9120Injection, dactinomycin, 0.5 mg
- J9130Dacarbazine, 100 mg
- J9144Injection, daratumumab, 10 mg and hyaluronidase-fihj
- J9145Injection, daratumumab, 10 mg
- J9150Injection, daunorubicin, 10 mg
- J9153Injection, liposomal, 1 mg daunorubicin and 2.27 mg cytarabine
- J9155Injection, degarelix, 1 mg
- J9161Injection, denileukin diftitox-cxdl, 1 mcg
- J9171Injection, docetaxel, 1 mg
Common questions about J9199
Is HCPCS J9199 still valid?
- No. J9199 was terminated on 06/30/2020.
Does Medicare cover J9199?
- Its coverage code is "C": coverage is left to the Medicare contractor's judgment. Check the local coverage determination for your region.